Cardiometabolic research / Depth-graded
MOTS-c type 2 diabetes research: blood sugar, the heart, and the cardiometabolic record
The diabetic-heart, islet, adipose, and human cardiovascular-risk evidence, consolidated — a thin lit band of human signal over a broad preclinical layer.
In plain English
This page gathers the MOTS-c type 2 diabetes evidence in one place. Type 2 diabetes is the condition where the body stops responding properly to insulin and blood sugar runs high. In mice and cells, MOTS-c helps muscle take up glucose and, in one 2025 rat study, helped diabetic hearts make energy more efficiently. In people, the signal is indirect: those who naturally carry less MOTS-c tend to have worse metabolic and heart-risk markers. So the animal story is encouraging, the human story is still observational, and no trial has yet given MOTS-c to people with diabetes to see what happens.
MOTS-c, glucose handling, and insulin sensitivity
MOTS-c type 2 diabetes research begins with glucose. In the founding 2015 work, MOTS-c prevented both age-dependent and high-fat-diet-induced insulin resistance in mice and identified skeletal muscle as the primary site of its glucose-handling effect, driven by AMPK activation [1]. Improving insulin sensitivity — how effectively cells respond to insulin to take up glucose — is the through-line of the metabolic literature [1][4]. The 2024 CK2 study sharpened the mechanism: MOTS-c activates casein kinase 2 in muscle to enhance glucose uptake, while suppressing it in fat [10].
Does MOTS-c help with type 2 diabetes or blood sugar?
In animal and cell studies MOTS-c improved glucose handling and insulin sensitivity, and a 2025 rat study restored cardiac mitochondrial respiration with lower fasting glucose [1][12]. There are no human efficacy trials, so this is research-stage only.
The diabetic heart and mitochondrial respiration
The cardiac evidence is recent and preclinical. A 2025 Frontiers in Physiology study used a rat model of type 2 diabetes (high-fat diet plus low-dose streptozotocin) and reported that MOTS-c increased OXPHOS respiration — the mitochondrial process that generates cellular energy — in cardiac mitochondria, with associated reductions in fasting glucose and left-ventricular hypertrophy [12]. A 2024 study in diabetic sand rats found that eight weeks of high- and moderate-intensity interval exercise altered mitochondrial MOTS-c and related metabolic markers in an intensity-dependent way, linking the body's own MOTS-c to exercise in a diabetic model [13]. Both are animal studies; each finding carries the preclinical grade.
What the human cardiovascular data shows
The strongest human-association data for MOTS-c is cardiometabolic, and it is observational. In a 2024 prospective multicenter cohort of 94 chronic hemodialysis patients, circulating MOTS-c was independently associated with a composite of all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, p=0.05) and improved a risk model's discrimination from ROC AUC 0.727 to 0.743 [11]. In children, circulating MOTS-c was lower in obese male children and adolescents and inversely associated with insulin resistance [5], and a separate pediatric cohort linked lower serum MOTS-c to vascular endothelial function [6]. These studies measure endogenous MOTS-c as a biomarker; they are surface-band human signal, not interventional outcomes.
The practical reading is that lower endogenous MOTS-c travels with worse cardiometabolic markers in the populations studied so far. That is an association, and association is not the same as a treatment effect. The hemodialysis cohort, with 94 patients, is the most informative human dataset, and its hazard ratio is small and at the threshold of significance (p=0.05) [11]. The pediatric studies are likewise modest in size [5][6]. None of these designs can show that raising MOTS-c — by exercise, by an analogue, or by exogenous peptide — changes a person's blood sugar, weight, or cardiovascular risk.
Stress-protection mechanisms that bear on cardiometabolic tissue
Several preclinical lines extend MOTS-c from glucose handling into tissue protection under metabolic and oxidative stress — relevant to cardiometabolic organs even where the studies are not framed as diabetes work. Under stress, MOTS-c translocates to the nucleus and drives AMPK-dependent regulation of antioxidant-response-element genes through NRF2 (the transcription factor that switches on a cell's antioxidant defenses), a pathway that protects cells from oxidative damage [3]. In a rodent cardiopulmonary-bypass model, MOTS-c promoted glycolysis via an AMPK-HIF-1alpha-PFKFB3 pathway and ameliorated bypass-induced lung injury [14]. In osteoarthritis models, MOTS-c attenuated mitochondrial dysfunction and cell death through an Nrf2-dependent mechanism [15].
These are mechanistically consistent with the cardiometabolic story — AMPK activation and NRF2-driven stress resilience recur across tissues — but they are distinct disease models, all preclinical, and none establishes a cardiometabolic outcome in humans [3][14][15].
MOTS-c, Fat Metabolism, and Weight in Animal Models
MOTS-c, Fat Metabolism, and Weight in Animal Models
In the founding study, MOTS-c prevented diet-induced obesity in mice rather than promoting weight gain, alongside its insulin-sensitizing effect [1]. A 2019 study showed MOTS-c regulated adipose-tissue homeostasis to prevent ovariectomy-induced metabolic dysfunction in mice, linking the peptide to estrogen-deficiency metabolic disease [7]. Mechanistically, the weight-relevant findings center on adipose thermogenesis (heat-producing activation of fat tissue) and CK2 suppression in fat [7][10]. All of these are animal-model findings; no human body-weight or fat-loss outcome data exist.
Does MOTS-c burn fat?
In mice MOTS-c prevented diet-induced obesity and increased adipose thermogenic activation; human fat-loss outcomes have not been tested [1][7].
Can MOTS-c cause weight gain?
In mice MOTS-c prevented diet-induced obesity rather than causing weight gain; no human body-weight outcome data exist [1].